产品
编 号：F759950
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 725735-28-4
产品详情
生物活性：
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer.
体内研究：
Intetumumab (CNTO 95; 10 mg/kg; i.p.; Male nude rats) inhibits tumor growth and inhibits spontaneous lung metastasis of A549 tumors and decreases both the number of rats with lung metastasis and the number of metastatic lesions per lung.Animal Model:Male nude rats with lung metastasis models (5-6 weeks old and 150-200 g)
Dosage:10 mg/kg
Administration:Intraperitoneal injection; once a week for 60 days
Result:Had the total tumor response rates (CR and PR) was 33% in A549 tumor model.Developed lung metastases only 4 of 9 rats.
体外研究：
Intetumumab (CNTO 95; 0-5 μg/mL; 20 min; USPC-ARK-3 cells) inhibits integrin-mediated USPC cell adherence to a vitronectin substratum and inhibits serum-induced migration of USPC cells.
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer.
体内研究：
Intetumumab (CNTO 95; 10 mg/kg; i.p.; Male nude rats) inhibits tumor growth and inhibits spontaneous lung metastasis of A549 tumors and decreases both the number of rats with lung metastasis and the number of metastatic lesions per lung.Animal Model:Male nude rats with lung metastasis models (5-6 weeks old and 150-200 g)
Dosage:10 mg/kg
Administration:Intraperitoneal injection; once a week for 60 days
Result:Had the total tumor response rates (CR and PR) was 33% in A549 tumor model.Developed lung metastases only 4 of 9 rats.
体外研究：
Intetumumab (CNTO 95; 0-5 μg/mL; 20 min; USPC-ARK-3 cells) inhibits integrin-mediated USPC cell adherence to a vitronectin substratum and inhibits serum-induced migration of USPC cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备